Clinical trials: Vehicle
Actinic Keratoses
Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis
At the end of the study, safety and efficacy outcome measures will be compared to determine a) if dosing with Generic Imiquimod cream, 5% is therapeutically equivalent to the currently marketed Aldara (imiquimod) cream, 5% and b)…
- Trial name
- NCT00948428
- Testing
- imiquimod, Aldara™, Vehicle Cream
- Where
- 20 sites in United States
- Volunteers
- 462 people
- Sponsor
- Actavis Inc.
Plaque Psoriasis
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)
This Phase 3 study has been designed to determine and compare the efficacy and safety of 000-0551 Lotion and Vehicle Lotion applied twice daily for two weeks in subjects with plaque psoriasis.
- Trial name
- NCT01871402
- Testing
- 000-0551 Lotion, Vehicle Lotion
- Where
- 10 sites in United States
- Volunteers
- 221 people
- Sponsor
- Therapeutics, Inc.
Heart Disease
Proteolytic Enzyme Induction Within the Human Myocardial Interstitium
A robust release of endothelin-1-1 (ET) with subsequent ETA subtype receptor (ET-AR) activation occurs in patients following cardiac surgery requiring cardiopulmonary bypass (CPB).
- Trial name
- NCT00744211
- Testing
- 1mg/kg sitaxsentan sodium, 2mg/kg sitaxsentan sodium, Vehicle
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- VA Office of Research and Development
Plaque Psoriasis
The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients
This study seeks to show whether there is a benefit of prescribing Enstilar in the treatment of patients with moderate plaque type psoriasis. Subjects will receive study treatment of Enstilar foam.
- Trial name
- NCT03848871
- Testing
- Enstilar
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Derm Research, PLLC
Alopecia Areata
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
Primary: To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA) Secondary: To evaluate key clinical outcome assessments
- Trial name
- NCT03354637
- Testing
- ATI-50002 high dose, ATI-50002 low dose
- Where
- 23 sites in United States
- Volunteers
- 129 people
- Sponsor
- Aclaris Therapeutics, Inc.
Common Wart
Study of A-101 Topical Solution for the Treatment of Common Warts
A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts
- Trial name
- NCT03687372
- Testing
- A-101, vehicle
- Where
- 24 sites in United States
- Volunteers
- 503 people
- Sponsor
- Aclaris Therapeutics, Inc.
Rosacea, Erythema
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
This study will evaluate the safety and tolerability of AGN-199201 for the treatment of erythema associated with rosacea.
- Trial name
- NCT01579084
- Testing
- AGN-199201 Formulation A, AGN-199201 Formulation B, AGN-199201 Formulation C
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Allergan
Healthy
A 4-Day Study to Evaluate the Photoxicity of Diacerein 1% Topical Ointment in Healthy Volunteers
This study was designed to assess the phototoxic potential of diacerein 1% ointment when application is followed by light exposure.
- Trial name
- NCT03473184
- Testing
- Diacerein 1% ointment
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Castle Creek Pharmaceuticals, LLC
Androgenetic Alopecia
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK.
- Trial name
- NCT06393452
- Testing
- PP405 0.05% Topical Gel, Topical Vehicle Gel
- Where
- 8 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Pelage Pharmaceuticals, Inc.
Knee Osteoarthritis
Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis
This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intra-articularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic…
- Trial name
- STRIDES-Xray (NCT03928184)
- Testing
- Lorecivivint
- Where
- 99 sites in United States
- Volunteers
- 501 people
- Sponsor
- Biosplice Therapeutics, Inc.
Acne Vulgaris
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
The aim of this study is to test the safety and efficacy of photodynamic therapy (PDT) for the medication Ameluz® performed with the PDT-lamp BF-RhodoLED® in comparison to the respective placebo treatment for moderate to severe…
- Trial name
- NCT05080764
- Testing
- 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Biofrontera Inc.
Dry Eye Syndrome
Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome
The objective of this study is to identify the concentration and daily dosing frequency of BOL-303242-X ophthalmic suspension in treating dry eye syndrome over a 12 week dosing period.
- Trial name
- NCT01163643
- Testing
- 0.3% BOL-303242-X ophthalmic suspension, 2% BOL-303242-X ophthalmic suspension, 1% BOL-303242-X ophthalmic suspension
- Where
- United States
- Volunteers
- 356 people
- Sponsor
- Bausch & Lomb Incorporated
Actinic Keratosis
Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities
The purpose of this study is to determine if Levulan Photodynamic Therapy (PDT) is safe and effective in the treatment of actinic keratoses on the upper arms and hands
- Trial name
- NCT02137785
- Testing
- Aminolevulinic Acid (ALA), Topical Solution Vehicle, Blue Light Photodynamic Therapy Illuminator (BLU-U)
- Where
- 13 sites in United States
- Volunteers
- 269 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Dry Eye Syndrome
A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye
The objective of this study is to assess the efficacy and safety of rhNGF eye drops at 20 μg/ml concentration administered two or three times daily for 4 weeks in patients with moderate to severe dry eye.
- Trial name
- NCT03982368
- Testing
- rhNGF 20 μg/ml, rhNGF 20 μg/ml + vehicle, Vehicle
- Where
- 12 sites in United States
- Volunteers
- 261 people
- Sponsor
- Dompé Farmaceutici S.p.A
Acne Vulgaris
Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)
The purpose of this trial is to study the efficacy and safety of Visonac PDT in patients from 9 to 35 years old with Aktilite® CL512.
- Trial name
- NCT00933543
- Testing
- Visonac PDT (MAL PDT), PDT
- Where
- 11 sites in United States, Canada
- Volunteers
- 107 people
- Sponsor
- Photocure
Hypotrichosis
Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily to the upper eyelid margins (where the eyelashes meet the skin) compared with vehicle in increasing overall eyelash prominence in…
- Trial name
- NCT00958035
- Testing
- bimatoprost ophthalmic 0.03% solution
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Allergan
Scalp Psoriasis
Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp
The primary objective of this study is to evaluate the safety and efficacy of clobetasol propionate spray versus vehicle spray for the management of moderate to severe plaque psoriasis of the scalp.
- Trial name
- NCT00881868
- Testing
- clobetasol propionate spray 0.05%, Vehicle spray
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Galderma R&D
Rhinitis, Allergic, Perennial and Seasonal
A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis
This phase IV investigational trial is being conducted to evaluate the efficacy of a 2-week treatment of fluticasone propionate nasal spray (FPNS) vs.
- Trial name
- NCT01916226
- Testing
- FPNS, Cetirizine
- Where
- 31 sites in United States
- Volunteers
- 682 people
- Sponsor
- GlaxoSmithKline
Ocular Inflammation
Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers
The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy in topical administration of differing dosing regimens of ISV-303 compared to vehicle and Xibrom™ when dosed for 2 weeks in…
- Trial name
- NCT01190878
- Testing
- ISV-303, DuraSite Vehicle, Xibrom™
- Volunteers
- 169 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Actinic Keratosis
Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
The purpose of the study is to demonstrate that ingenol mebutate gel is efficacious in treating Actinic Keratoses (AKs) present 8 weeks after initial field treatment or emerging in a previously cleared field.
- Trial name
- NCT01600014
- Testing
- Ingenol mebutate gel, 0.015%, Vehicle gel
- Where
- 13 sites in Australia, Canada and 3 more
- Volunteers
- 463 people
- Sponsor
- LEO Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.